Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

(2020) Mitsunori Morita et al.   BMC CANCER

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

(2020) Matthias Pinter et al.   GUT

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma

(2020) Matthias Pinter et al.   JAMA Oncology

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study

(2020) Jakob M. Riedl et al.   Cancers

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

(2020) Tsuguru Hayashi et al.   PLoS One

Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma

(2020) Stephan Spahn et al.   Cancers

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort

(2019) Bernhard Scheiner et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation

(2019) Tobias Meischl et al.   PLoS One

Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

(2019) Peter R. Galle et al.   LIVER INTERNATIONAL

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

(2019) Chandan Sanghera et al.   LIVER INTERNATIONAL

C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions

(2019) Rachel V. Jimenez et al.   Frontiers in Immunology

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma

(2018) Vincenzo Mazzaferro et al.   GASTROENTEROLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma

(2018) Hitomi Takada et al.   PLoS One

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers

(2018) Takaki Akamine et al.   SURGICAL ONCOLOGY-OXFORD

Review article: systemic treatment of hepatocellular carcinoma

(2018) Matthias Pinter et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

(2017) Daniela Sia et al.   GASTROENTEROLOGY

Usefulness of a new inflammation-based scoring system for prognostication of patients with hepatocellular carcinoma after hepatectomy

(2015) Shozo Mori et al.   AMERICAN JOURNAL OF SURGERY

Towards better clinical prediction models: seven steps for development and an ABCD for validation

(2014) E. W. Steyerberg et al.   EUROPEAN HEART JOURNAL

How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma

(2014) Florian Hucke et al.   JOURNAL OF HEPATOLOGY

Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells

(2014) Angela D. Pardee et al.   JOURNAL OF IMMUNOLOGY

Cancer-related inflammation and treatment effectiveness

(2014) Connie I Diakos et al.   LANCET ONCOLOGY

Alpha-fetoprotein: a renaissance

(2013) A. A. Terentiev et al.   TUMOR BIOLOGY

The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer

(2012) Donald C. McMillan   CANCER TREATMENT REVIEWS

Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

(2012) Christophe Duvoux et al.   GASTROENTEROLOGY

Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma

(2012) Wolfgang Sieghart et al.   HEPATOLOGY

A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI)

(2012) David J. Pinato et al.   JOURNAL OF HEPATOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma

(2011) Gia L. Tyson et al.   Clinical Gastroenterology and Hepatology

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data

(2011) Hajime Uno et al.   STATISTICS IN MEDICINE

Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression

(2010) Eek Joong Park et al.   CELL

Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status

(2010) Yun-feng Shan et al.   MEDICAL ONCOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Assessing the Performance of Prediction Models

(2009) Ewout W. Steyerberg et al.   EPIDEMIOLOGY

Ikappa B kinaseβ/nuclear factor-κB activation controls the development of liver metastasis by way of interleukin-6 expression

(2009) Shin Maeda et al.   HEPATOLOGY

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE